Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-250 vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Intravascular use for computed tomography (CT) of the head and body,Intrathecal use for lumbar, thoracic, and cervical myelography,Coronary arteriography and ventriculography,Peripheral arteriography,Excretory urography,Visceral angiography
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Iopamidol is not metabolized. It is excreted unchanged by glomerular filtration, primarily via the kidneys. In patients with normal renal function, 90% or more of the administered dose is eliminated in the urine within 24 hours.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
<5% bound; primarily to albumin
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
0.2-0.3 L/kg; reflects distribution in extracellular fluid (does not cross intact blood-brain barrier)
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Intravascular: 100%; oral: negligible (<1%)
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
e GFR <30 m L/min/1.73m²: avoid use or use minimal dose with adequate hydration; e GFR 30-59: consider lowest effective dose and ensure hydration; no specific dose reduction for e GFR ≥60.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
No specific Child-Pugh based dose modifications; use with caution in severe hepatic impairment due to potential contrast-induced nephropathy risk.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Children: 1-2 m L/kg (250-500 mg iodine/kg) intravenously for CT, not to exceed adult dose; adjust for body weight and procedure.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Elderly patients: use lowest effective dose; ensure adequate hydration; monitor renal function closely due to age-related decline and increased risk of nephropathy.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Intrathecal administration may result in neurotoxicity including seizures, meningitis, and arachnoiditis. Inadvertent intravascular injection during intrathecal administration may cause serious adverse reactions.
None
Do not use for myelography if procedures are contraindicated,Risk of serious adverse reactions in patients with impaired renal function, including acute renal failure,Risk of cardiorespiratory arrest, anaphylactic shock, and other severe allergic reactions,Potential for thyroid storm in patients with hyperthyroidism,Caution in patients with pheochromocytoma, sickle cell disease, and multiple myeloma
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
History of severe allergic reaction to iopamidol or any component of the formulation,Intrathecal administration in patients with thrombophlebitis, infection, or malignancy at the injection site,Severe renal impairment (anuria, oliguria) unless the benefits outweigh the risks,Patients with a history of grand mal seizures, or those on drugs that lower seizure threshold, for intrathecal use
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
No known food interactions. However, ensure adequate hydration before and after the procedure. Avoid alcohol 24 hours prior as it may increase risk of dehydration.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated contrast agents cross the placenta and may produce transient neonatal hypothyroidism if used in the third trimester. However, data from clinical studies are insufficient to determine a definitive teratogenic risk. First trimester exposure has not been associated with major congenital malformations, but caution is warranted due to potential fetal hypothyroidism with prolonged use near term.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Limited data suggest that iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not specifically reported for iopamidol, but for similar iodinated contrast agents, the M/P ratio is low (<0.2). The amount of iodine transferred to the infant is negligible and unlikely to cause adverse effects. However, the American College of Radiology and other guidelines recommend that breastfeeding may be continued without interruption after receiving iodinated contrast, although some advise discarding milk for 12-24 hours if the mother is concerned.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
Pregnancy does not require dose adjustments for ISOVUE-250. The dose should be based on the diagnostic procedure and patient weight. However, because of potential fetal hypothyroidism risk from free iodide, alternative imaging modalities without iodinated contrast should be considered if possible, especially in the third trimester.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
ISOVUE-250 (iopamidol 51%) is a nonionic, low-osmolality iodinated contrast medium used for angiography, urography, and CT enhancement. In patients with renal impairment (e GFR <30 m L/min), consider N-acetylcysteine prophylaxis and hydration to reduce risk of contrast-induced nephropathy. Monitor for delayed hypersensitivity reactions, which can occur up to 7 days post-administration. Use caution in patients with pheochromocytoma; pre-treat with alpha-blockers. Shellfish allergy is not a contraindication; true iodine allergy is rare. For intrathecal use, avoid concurrent neurotoxic drugs and ensure patient hydration.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Inform your doctor if you have kidney disease, diabetes, or are taking metformin; metformin may need to be stopped temporarily.,Tell your doctor about all allergies, especially to medications or iodine.,You may feel warmth, flushing, or a metallic taste when the contrast is injected; this is normal.,Drink plenty of water before and after the procedure to help flush the contrast from your body.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/mouth immediately.,If you are pregnant or breastfeeding, discuss potential risks with your doctor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-250 vs ANDROID 10, answered by our medical review team.
ISOVUE-250 is a Contrast Media that works by Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-250 and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-250 is: Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-250 and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-250 is classified as Category C. ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.